1. Home
  2. PRLB vs NUVB Comparison

PRLB vs NUVB Comparison

Compare PRLB & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLB
  • NUVB
  • Stock Information
  • Founded
  • PRLB 1999
  • NUVB 2018
  • Country
  • PRLB United States
  • NUVB United States
  • Employees
  • PRLB N/A
  • NUVB N/A
  • Industry
  • PRLB Metal Fabrications
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRLB Industrials
  • NUVB Health Care
  • Exchange
  • PRLB Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • PRLB 824.1M
  • NUVB 679.9M
  • IPO Year
  • PRLB 2012
  • NUVB N/A
  • Fundamental
  • Price
  • PRLB $33.36
  • NUVB $1.97
  • Analyst Decision
  • PRLB Buy
  • NUVB Strong Buy
  • Analyst Count
  • PRLB 4
  • NUVB 5
  • Target Price
  • PRLB $43.67
  • NUVB $8.00
  • AVG Volume (30 Days)
  • PRLB 257.1K
  • NUVB 3.3M
  • Earning Date
  • PRLB 05-02-2025
  • NUVB 05-13-2025
  • Dividend Yield
  • PRLB N/A
  • NUVB N/A
  • EPS Growth
  • PRLB 0.37
  • NUVB N/A
  • EPS
  • PRLB 0.66
  • NUVB N/A
  • Revenue
  • PRLB $500,890,000.00
  • NUVB $7,873,000.00
  • Revenue This Year
  • PRLB $3.49
  • NUVB $75.73
  • Revenue Next Year
  • PRLB $4.82
  • NUVB $440.21
  • P/E Ratio
  • PRLB $50.55
  • NUVB N/A
  • Revenue Growth
  • PRLB N/A
  • NUVB N/A
  • 52 Week Low
  • PRLB $25.76
  • NUVB $1.54
  • 52 Week High
  • PRLB $46.73
  • NUVB $3.97
  • Technical
  • Relative Strength Index (RSI)
  • PRLB 41.83
  • NUVB 52.62
  • Support Level
  • PRLB $32.57
  • NUVB $1.82
  • Resistance Level
  • PRLB $35.38
  • NUVB $2.08
  • Average True Range (ATR)
  • PRLB 1.81
  • NUVB 0.18
  • MACD
  • PRLB 0.13
  • NUVB 0.04
  • Stochastic Oscillator
  • PRLB 55.69
  • NUVB 79.63

About PRLB Proto Labs Inc. Common stock

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: